CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Diana Moser has, to the best of her knowledge, not contracted Lyme disease, a welcome status quo that might be credited to ...

OneSource Specialty Pharma partners with Xbrane Biopharma for biosimilar manufacturing, aiming to strengthen global supply ...

Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets.

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...

OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio ...

The US Food and Drug Administration (FDA) will in future recognize a relevant reduction in the amount of alcohol consumed by ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Results from the study’s open-label period, presented at this year’s European Renal Association Congress, showed that ...

Bulgaria wants areas of national competence respected, especially for drug reimbursement decisions to remain within the member states.

SIFI, a leading international ophthalmic company, today announced that its shareholders have signed an agreement, subject to conditions precedent, to sell 100% of SIFI shares to Faes Farma, a leading ...